Applied Medical Resources Corporation
$1.9M 2,197 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Acrotech Biopharma Inc.
Acrotech Biopharma Inc. reported $1,915,377.70 across General Payments, Research, and Ownership to 1,589 physicians and teaching hospitals across 1,834 transactions.
- $1.9M Top quartile payer
- All-tracks total
- 1,834 Top quartile volume
- Transactions
- 1,589 Top quartile reach
- Recipients
- −$83.6K
- General Payments vs PY2023
Acrotech Biopharma Inc. reported $1,915,377.70 across all CMS Open Payments tracks (General + Research + Ownership) to 1,589 physicians and teaching hospitals in Program Year 2024 - ranking #458 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $317,860.76, averaging $1.2K per recipient.
How Acrotech Biopharma Inc.'s $1.9M all-tracks total breaks down
Acrotech Biopharma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
43/100
Total payments
F
28/100
Transaction volume
F
23/100
Physician reach
F
22/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer acrotech-biopharma-inc Acrotech Biopharma Inc.
$1.9M · #458/1,925 · 0.0% industry · PY2024
- TOT $1.9M
- RANK #458
- SHARE 0.0%
- TXN 1,834
- RCP 1,589
- CAT 8
- GEN $317.9K
- ΔGEN −$83.6K
- TOP1 25.2%
- PY 2024
Volume peers
Nearest volume peer: Applied Medical Resources Corporation ($1.9M)
Acrotech Biopharma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Acrotech Biopharma Inc.'s CMS-reported General Payments decreased by $83.6K (−20.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ACROTECH BIOPHARMA INC.PY2023: ACROTECH BIOPHARMA INC.PY2024: Acrotech Biopharma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $401,424.10
- PY2024
- $317,860.76
What the Data Shows for Acrotech Biopharma Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Acrotech Biopharma Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
38 transactions worth $112.3K make "Consulting Fee" the top general-payment category in the 8-category breakdown below, 35.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Acrotech Biopharma Inc. made 8 types of general payments. "Consulting Fee" is the largest category at $112.3K, 35.3% of General Payments.
Acrotech Biopharma Inc. reports 8 general-payment categories - the top three are Consulting Fee (35.3%), Grant (22.0%), and Compensation for Services Other Than Consulting (12.8%). The remaining 5 categories make up 29.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Acrotech Biopharma Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Acrotech Biopharma Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $112.3K | 38 | 35.3% |
| Grant | $70.0K | 1 | 22.0% |
| Compensation for Services Other Than Consulting | $40.8K | 52 | 12.8% |
| Food and Beverage | $36.3K | 1,393 | 11.4% |
| Travel and Lodging | $28.4K | 89 | 8.9% |
| Space Rental or Facility Fees | $26.8K | 9 | 8.4% |
| Honoraria | $3.3K | 2 | 1.0% |
| Education | $69.65 | 5 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $138,957.74 (43.7%) of $317,860.76 in this company's General Payments records across 1,097 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Acrotech Biopharma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
University of Virginia Medical Cente
$80,000.01 across 4 reported transactions
- 2
Hayder Saeed
$21,769.62 across 9 reported transactions
- 3
Matthew Lunning
$14,795.95 across 16 reported transactions
- 4
Francine Foss
$13,200.74 across 8 reported transactions
- 5
John Glaspy
$9,191.42 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Acrotech Biopharma Inc. ranks #458 of 1,925 by total payments (top 24% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,120 of 1,838 by HHI (bottom 39% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Terumo Cardiovascular Systems Corporation : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
- Acrotech Biopharma Inc. (this company) : $317.9K total payments, HHI 793
- KaVo Dental Technologies LLC : $990.42 total payments, HHI 792
- Creo Medical Inc. : $263.8K total payments, HHI 789
- Progenics Pharmaceuticals, Inc. : $1.7M total payments, HHI 786
- ABB Con-Cise Optical Group LLC : $238.5K total payments, HHI 784
- Vantage Technology LLC : $593.80 total payments, HHI 784
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Acrotech Biopharma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Acrotech Biopharma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Acrotech Biopharma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vasorum USA Inc.
$1.9M 59 recipients
Compare payment profiles
Spark Therapeutics, Inc.
$1.9M 146 recipients
Compare payment profiles
Procyrion, Inc.
$1.9M 211 recipients
Compare payment profiles
PROCEPT BioRobotics Corporation
$1.9M 8,013 recipients
Compare payment profiles
CooperSurgical, Inc.
$1.9M 9,542 recipients
Compare payment profiles
Put this to use
Acrotech Biopharma Inc. ranks #458 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Acrotech Biopharma Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Acrotech Biopharma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.